INTRODUCTION
Genetic and epigenetic alterations can act together to release a cell from its normal growth constraints, enabling formation of a primary tumor (1) . Expression of growth-critical proteins is regulated at multiple levels by disparate stimuli. Protein expression is controlled at the level of translation primarily through the activity of messenger RNA (mRNA) capbinding protein eukaryotic initiation factor 4E (eIF-4E), which is frequently upregulated in tumors (2) (3) (4) . The second generation 20-mer antisense oligonucleotide (ASO), LY2275796, was designed to bind to human eIF-4E mRNA. While first generation ASOs contained a phosphorothioate (a sulphur substitution of a nonbridging O) backbone, second generation ASOs, contain the phosphorothioate backbone plus the addition of 2' O-methoxyethyl modification of riboses at the 5' and 3' ends. These modifications enhance affinity for target RNA, thus improving stability and potency, improving antitumor potential and decreasing toxicity (5, 6) . As with other ASOs, inhibition of gene expression is mainly accomplished by recruitment of endogenous RNase H (7) (8) (9) .
In preclinical studies, administration of LY2275796 to tumor-bearing mice resulted in a dose-related reduction in eIF-4E, protein expression, and supression of tumor growth (8) . The high dose of 25 mg/kg LY2275796 resulting in a 56% reduction in eIF4E protein expression relative to the mismatch control ASO and tumor growth suppression as assessed by no increase in tumor volume. Treatment with 5 mg/kg or 12.5 mg/kg dose group, showed statistically non-significant reduction in eIF4E expression, with no and intermediate reduction in tumor growth, respectively (8) . Measures of generalized toxicity, body weight, organ weight, and liver transaminase levels were not affected despite an 80% reduction of eIF-4E levels in the liver, an organ where ASOs preferentially accumulate.
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Author Manuscript Published OnlineFirst on August 10, 2011; DOI: 10.1158/1078-0432. In the Phase I clinical trial summarized here, a dose escalation design was used to determine a Phase 2 LY2275796 dose that could be safely administered to patients with advanced solid tumors. Secondary objectives of this study were to characterize LY2275796 toxicities, determine its effect on eIF-4E expression, estimate its pharmacokinetic parameters, explore pharmacokinetic-pharmacodynamic relationships, and document antitumor activity.
Research. 
MATERIALS AND METHODS

Patient Selection
Eligibility criteria included histologic or cytologic documentation of a malignancy for which no proven therapy exists; discontinuation of previous cancer therapies for ≥4 weeks; performance status (PS) 0/1 on the Eastern Cooperative Oncology Group (ECOG) scale (10); age ≥18 years; and written informed consent. Other criteria were adequate bone marrow, liver, and renal (11) function and adequate coagulation (activated partial thromboplastin time [aPTT] and prothrombin time [PT] ≤ upper limit of normal). In parts B and C of the study, patients were to have disease amenable to biopsy.
Key exclusion criteria included previous treatment with antisense therapies; serious pre-existing medical conditions; and symptomatic central nervous system metastasis, hematological malignancies, or bleeding diathesis. Anticoagulant therapy (with the exception of the use of heparinized saline to maintain the patency of central venous catheters) was prohibited.
Dose Selection
Research. An indirect PK-PD model was fitted to the tumor-bearing mouse model preclinical data (8) to describe the relationship between concentration and target inhibition. The model indicated that LY2275796 plasma exposure/concentrations of 297300 ng/h/mL, 65910 ng/mL (Cmax) and 96 ng/mL (Ctrough or Cmin concentration) would be needed to achieve the 50-60% inhibition of target expression shown in the preclinical model to be necessary for tumor growth suppression. The preclinical model indicated that LY2275796 dose level of 800 mg (or greater) given daily for three days (loading doses on day 1, day 2, and day 3) and weekly thereafter (maintenance doses starting day 8) would lead to the targeted exposure.
A maximum tolerated dose (MTD) was not defined in the preclinical safety studies and a lowest no observed-adverse-effect level (NOAEL) for LY2275796 was defined at 5 mg/kg in mice and 2 mg/kg in monkeys. The pharmacokinetics of LY2275796 were characterized in monkeys following single and multiple doses in the toxicology study, with the monkey pharmacokinetic parameters then scaled to predict the human LY2275796 pharmacokinetics. Plasma concentrations following different doses were simulated in humans using the predicted human PK parameters. Data supported fixed-dose administration rather than dosing normalized by body weight or surface area. The proposed starting dose was 100 mg, which is approximately 1.3 mg/kg assuming an average weight of 75 kg. This dose had been shown to be tolerated in clinical studies with other ASOs and PK modeling predicted peak plasma concentrations following a 3-hour infusion, as had been found with a similar dose with other ASOs.
Study Design and Treatment Scheme
Research. This was a nonrandomized, dose-escalating, Phase 1 investigation of LY2275796 (Accession # M15353, nucleotide 1285-1304), administered intravenously as a loading dose over 3 days, and thereafter as a weekly maintenance dose ( Figure A ; Supplementary data, online-only). In part A of the three-part study, the drug dose was escalated by increments of ≤100%, using single patient cohorts, until a significant toxicity was observed, or ongoing pharmacokinetic modeling suggested the need for pharmacodynamic data. In part B, the study drug dose was escalated by increments of ≤50%, using three-patient minimum cohorts, until a dose-limiting toxicity (DLT) was observed, or until the biological effective dose (BED) was established after considering the maximum tolerated dose Patients remained on the study until progressive disease, a DLT, requested discontinuation, or non-compliance.
Treatment could be delayed up to 2 weeks to allow hematological toxicities to resolve to ≤grade 2, and non-hematological toxicities to ≤grade 1. Patients experiencing a DLT could be dose-reduced to the previous dose level, if they recovered sufficiently from the toxicity. Patients requiring a second dose reduction or experiencing a DLT in the first week of treatment were discontinued from the study.
Baseline and Treatment Assessments
Baseline assessments included medical history, vital signs, PS, radiologic tumor measurement, and measurement of palpable or visible lesions. Hematology, coagulation, blood chemistry, complement split products, and platelet activation markers were assessed at baseline, following cycle 1 and 2 infusions, and as needed following later cycle infusions. Hematologic and nonhematologic data were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) rating scale, Version 3.0 (12) .
At the discretion of the investigator, tumor response was assessed at intervals using Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 guidelines (13) .
Pharmacokinetic and Pharmacodynamic Analyses
Plasma samples were collected at prespecified intervals for determination of LY2275796 concentrations using a validated enzyme-linked immunosorbent assay at a central laboratory. Patients participating in parts B and C of the study had pre-treatment tumor biopsies collected within 4 weeks before day 1 of the loading dose. Post-treatment biopsies were collected between days 21 through 28, and for some patients, an additional biopsy between days 8 through 11, times chosen to correspond to the expected timing of protein and mRNA reduction, respectively. To determine the pharmacodynamic effect of LY2275796, a validated branched DNA (bDNA) assay was used to measure eIF-4E mRNA, and immunohistochemistry was used to measure eIF-4E protein content using a mouse monoclonal antibody (BD Biosciences, clone 87). Tumor tissue samples were also analyzed by immunohistochemistry for related downstream markers of pharmacology and tumor growth using mouse monoclonal antibodies raised against Cyclin D1 (Novocastra, clone P2D11F11) and vascular endothelial growth factor (VEGF; Novus Biologicals, clone VG1).
Statistical Evaluation Methods
Pharmacokinetic, safety, and response data were analyzed for all patients who received at least one dose of LY2275796.
A non-linear mixed effect modeling technique (NONMEM, version VI) was used to
analyze plasma LY2275796 data (log-transformed), allowing estimation of mean pharmacokinetic parameter values and inter-individual and intra-individual variability.
Model parameters were estimated using the first order conditional estimation method with interaction (14) . The inter-individual and intra-individual variability were coded as an exponential and a proportional relationship, respectively. Three and four compartmental pharmacokinetic models with elimination from the peripheral compartment and a similar elimination rate constant were fitted to the pharmacokinetic data. This approach was justified since second generation ASOs distribute extensively into tissues with different rates of uptake depending on tissue type (15). Additionally, ASOs are cleared through tissue nuclease cleavage; hence, the elimination rate in the peripheral compartment is To quantify eIF-4E mRNA expression using the bDNA assay, the ratio of geometric means for post-dose to pre-dose eIF-4E expression was computed using a mixed model on log-transformed data with patient as a random factor and time as a fixed factor (preand post-dose). The log-transformed mean of the three available housekeeping genes (Actin B, HPRT1, RPS20) was to be used to normalize the ratio of geometric means for post-dose to pre-dose eIF-4E mRNA expression. 
RESULTS
Patients
Beginning January 2006 at two study centers, 30 patients enrolled and received at least one dose of study drug, with the last patient completing the study in March 2009. Table 1 summarizes patient demographics and disease characteristics. The allocation of patients among the three study parts (A-C), cohorts, and doses is summarized in Figure B (Supplemenatry data, online-only).
Treatment
Patients received a median of two completed cycles, with a range of one-to-five, and a total of 81 cycles during which 94% of the doses were given as planned). The most common reasons for study discontinuation were progressive disease (17 patients, 56.7%), followed by patient decision and physician decision (five patients each, 16.7%), and patient death (two patients, 6.7%). Additionally, one patient discontinued because of congestive heart failure, an event considered possibly study drug and protocol procedure-related, with the intravenous fluids necessary to administer the study drug as a possible contributing factor.
Among the 267 infusions of LY2275796 planned, 251 were administered (treatment compliance rate 94.0%), two (0.7%) were withdrawn, and 14 (5.2%) were omitted. Both dose withdrawals and most dose omissions (nine of 14, 64.3%) were attributed to adverse events (AEs). There were no dose reductions.
Biologically Effective Dose and Toxicity
The study proceeded through part A and B of the dose escalation scheme ( fatigue was observed in one of six patients dosed at this level. In addition, three of the six patients at 1200 mg had doses interrupted or withdrawn because of grade 1/2 AEs (pruritus, chills, hypersensitivity, pyrexia). The decision to designate 1000 mg as the MTD and the BED was based on an integrated analysis of the clinical, pharmacokinetic, and pharmacodynamic observations. Clinically, the 1200 mg dose was associated with dose delays and toxicities, whereas the 1000 mg dose had been well tolerated. Taken together, the pharmacokinetic differences (Table 3) did not suggest a substantial change between 1000 mg and 1200 mg. Finally, the assayed biomarkers (immunohistochemistry staining from baseline of eIF-4E nuclear, cytoplasmic; bDNA of eIF-4E gene, mRNA expression)
showed little change between the 1000 mg dose and the 1200 mg dose. Table 2 summarizes the toxicities at all dose levels possibly related to study drug according to investigator assessment. Across all dose levels, most (87%) patients had no or only low grade (1/2) toxicities; no grade 4 toxicities were reported. Four patients reported grade 3 toxicities: two patients with fatigue; one patient each with thrombocytopenia and lymphopenia. Fatigue (47%), nausea (33%), fever (27%), and vomiting (20%) were among the most frequently reported low-grade non-laboratory AEs.
Prolongation of aPTT (37%) and PT (30%) and thrombocytopenia (17%) were the most frequently reported laboratory toxicities. Generally, the aPTT returned to baseline values within 24 hours, and only one patient experienced epistaxis (grade 1). Three patients required transfusions of packed red blood cells on study: two patients (both 1000 mg dose) received one transfusion each after a drop in hemoglobin level, and one patient (800 mg Four patients died while on study, three from progressive disease and one secondary to multi-organ failure, attributed to disease progression or non-study drugrelated sepsis.
Efficacy
Of the 30 patients who received at least 1 dose of LY227596, 22 had at least one post-baseline reassessment by RECIST. Among these patients, 15 patients had progressive disease, and seven patients achieved stable disease (minimum of 6 weeks) as best response, with two patients on therapy >3 months (one with melanoma, one with cystadenocarcinoma of the head/neck). Among the patients with no post-baseline response assessment, four discontinued from the study, two died (one due to disease progression, the other from non-drug-related multi-organ failure), and one patient each discontinued for clinical progression and congestive heart failure.
Pharmacokinetics
Fitting the data to a multicompartment model, with the rate of input into circulation determined by the rate of intravenous infusion, the distribution of LY2275796 into tissue and its elimination from plasma were found to occur at multiple rates or half-lives, leading to different concentrations in different tissues (Figure 1) . The half-lives of these disposition phases were approximately 9 minutes, 2 hours, 5 hours, and 15 days, accounting for approximately 11%, 74%, 11%, and 4% of the overall plasma exposure, respectively, and indicating that the majority of the plasma exposure is distributed into the tissues within 24 hours of administration. The terminal elimination phase half-life of 15 days (range 9 to 25
Research. details the compartmental pharmacokinetic model parameters. Table 3 summarizes the LY2275796 plasma pharmacokinetic parameters illustrating that the increase in LY2275796 exposure is less than dose proportional. No significant accumulation in plasma exposure (Cmax and AUC from 0-24 hours) was observed over the first month of treatment (loading and maintenance doses).
Pharmacodynamics
Of the 25 patients in parts B and C, each had a pre-treatment biopsy; 18 patients also had a biopsy 21-28 days post-treatment, and three patients had a second posttreatment biopsy 8-11 days post-treatment. Due to the limited quantity of tumor tissue in some biopsies, not all immunohistochemistry and bDNA assays were performed on each biopsy. Compared to pre-treatment tumor biopsies, post-treatment tumor biopsies in patients receiving the BED (1000 mg) or more, showed a reduction in cytoplasmic expression of eIF-4E protein in nine of twelve patients, while the nuclear eIF-4E protein level was reduced in three of six patients (Figure 2,3) . Likewise, at doses ≥1000 mg, cytoplasmic VEGF was reduced in eight of twelve patients, nuclear VEGF in five of eleven patients, cytoplasmic Cyclin D1 in two of four patients, and nuclear Cyclin D1 in five of eleven patients.
Using the bDNA assay to quantify eIF-4E gene expression, eIF-4E mRNA was found to be reduced in six of seven evaluable pairs. The estimate of the ratio of the least 
DISCUSSION
Using a loading and maintenance dose regimen, the MTD and BED of the eIF-4E ASO, LY2275796, was identified as 1000 mg. LY2275796 was well tolerated with a low rate of grade 3/4 toxicity. The only DLT noted was grade 3 fatigue (at 1200 mg). As observed with other ASOs, by some unknown mechanism, a portion of the patients (37%) exhibited aPTT prolongation; however, it was grade 1/2 and recovered to baseline levels within 24 hours. Low grade fatigue and fever were also observed, similar to the febrile events noted with other ASOs, and thought to be non-sequence specific and related to the polyanionic nature of these compounds and their effects on cytokine release. bDNA at doses ≥1000 mg (Figures 2,3) . Two targets of eIF-4E, VEGF and cyclin D1, were also found by immunohistochemistry to be reduced (~35-60%) in some patients, but not all. Notably, the bDNA assay is a more sensitive and quantitative assay while immunohistochemistry allows assessment of biomarker expression in viable tumor cells.
Limitations include inherent sampling error associated with tumor biopsies, the relatively small number of subjects, and the inability to normalize the mRNA results due to apparent downward change of housekeeping gene expression which may also be related directly to eIF-4E inhibition..
Our determination of BED at 1000mg was based on both the pharmacokinetic and pharmacodynamic findings in the study. Pharmacokinetic and pharmacodynamics parameters did not change substantially from the 1000 mg to the 1200 mg dose.
Additionally, there was an increase in toxicity and decreased tolerability at the 1200 mg dose. The preclinical models had shown a 50-60% knockdown in eIF4E protein was sufficient for tumor growth suppression in a tumor-bearing mouse model (8) . In our study we observed an 80% reduction in eIF-4E mRNA in post-treatment biopsies as compared to pretreatment biopsies. In addition, we observed a reduction in cytoplasmic expression of eIF-4E protein in nine of twelve patients and nuclear eIF-4E protein in three of six patients.
Although, eIF-4E mRNA and nuclear protein expression were reduced in most tumor biopsies, no tumor responses were observed. Possibly, the eIF-4E downregulation achieved clinically is not as robust as that achieved in preclinical models where anti-tumor effects of eIF-4E downregulation were observed (8, 18) . Alternately, blocking a component of one of the protein translational complexes may not immediately result in cytotoxic/apoptotic events and tumor size reduction, as seen with cytotoxic agents.
Instead, the effect might be cytostasis, resulting in stable disease. However, the relatively low (32%) stable disease rate in this study and short duration (only 2 patients >3 months) would suggest that anti-tumor effects of LY2275796 might best be achieved in combination with chemotherapy or radiation.
The pharmacokinetic profile of LY2275796 in this first-in-human study matched the anticipated profile based on the model and supports the present dosing schedule of a 3-day consecutive loading dose followed by weekly maintenance dose. The 1000 mg dose level was identified as being well tolerated and effective at inhibiting eIF-4E mRNA and protein expression, with some evidence of the expression of two relevant downstream targets also being impacted. As with all ASO therapy, the main limitation of LY2275796 may be that it impacts a single target in a disease state maintained by genetically independent, functionally redundant alterations. Certainly, using LY2275796 ASO therapy in combination with other treatment modalities might achieve improved anti-tumor effects, 
